Diligent Unveils New Agentic Capabilities in Diligent One to Power the Future of Governance, Risk and Compliance

 New capabilities help organizations move from fragmented information to confident action while keeping people in control

 

(BUSINESS WIRE)--Diligent, the AI leader in governance, risk and compliance (GRC) solutions, today announced a major enhancement to Diligent One, its native AI platform, at Gartner’s Enterprise Risk, Audit and Compliance Conference (ERAC).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915941016/en/

“For many organizations, GRC work is slowed by fragmented systems, manual coordination and time-consuming reporting processes,” said Brian Stafford, President and CEO of Diligent. “Our latest agentic capabilities help teams cut through that complexity by connecting context, surfacing what matters and driving faster execution — while keeping governance and professional judgement at the center."

An orchestration agent that coordinates work and approvals

The orchestration agent in Diligent One gives GRC professionals a natural-language interface to coordinate audit and risk work. Instead of simply answering questions, it enables users to describe what they need, and routes work to the right specialized agents to execute workflows. Agents are built on Diligent One’s connected GRC data, giving them the domain knowledge to execute workflows across the audit and risk lifecycle, automating the work that slows practitioners down without replacing human judgement.

Through Diligent One, specialized agents:

Help risk teams move from periodic assessments to continuous management by working directly in Diligent Enterprise Risk Management. The agent monitors risk data, cleans records, coordinates assessments, follows up on overdue actions, escalates issues and surfaces emerging risks.

Help internal audit teams plan and execute audits faster by turning manual preparation into conversational workflows in Diligent Audit. The agent identifies relevant risks, maps them to audit objectives, links existing controls and supports evidence collection, testing and findings development.

In addition, AI reporting turns live risk and controls data into board-ready reports and insights on demand. Using conversational prompts or templates, teams can quickly surface key findings and generate polished, secure, source-cited reports in minutes instead of days — eliminating hours spent manually pulling together data, insights and presentations.

“Risk and audit teams are being asked to look beyond what happened yesterday and give the business the insights it needs to make better decisions today and tomorrow,” said Scott Bridgen, General Manager, Risk & Audit at Diligent. “That means moving from static, point-in-time reporting to always-on monitoring that can identify changes as they happen and trigger action in real time, with the right level of oversight, approval and accountability.”

AI that reasons like a GRC expert

At the foundation of Diligent One is the GRC brain, a connected intelligence layer that links regulations, obligations, policies, controls, risks, evidence and actions. By connecting this information, the GRC brain gives agents the domain knowledge to work like an experienced GRC practitioner, equipped with deep context of how information connects across the business.

This connected intelligence gives Diligent One’s agents the ability to reason across relationships to deliver sharper insights and clearly explain the rationale behind the recommendations. The result is practical, actionable intelligence that helps GRC teams prioritize work, surface potential gaps and respond more efficiently to emerging risks. The GRC brain will become available in select Diligent solutions in October.

Diligent is showcasing its latest agentic capabilities at Gartner ERAC in Dallas on September 15-16, Booth 201.

Learn more about Diligent’s AI capabilities at www.diligent.com/platform/diligent-ai

About Diligent

Diligent is the AI leader in governance, risk and compliance (GRC) solutions, helping more than 1 million users and 700,000 board members to clarify risk and elevate governance. The Diligent One Platform gives practitioners, the C-suite and the board a consolidated view of their entire GRC practice so they can more effectively manage risk, build greater resilience and make better decisions, faster. Learn more at diligent.com. Follow Diligent on LinkedIn and Facebook.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260915941016/en/

Permalink

https://aetoswire.com/en/news/54604218

Contacts

 

Media

Michele Steinmetz

Senior Director, Marketing Communications, Diligent

+1-215-817-5610

msteinmetz@diligent.com

 

Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems

 OSAKA, Japan & CAMBRIDGE, Mass. -

2026 Awardees are Corus International, Humanity & Inclusion Handicap International, Kwame Nkrumah University of Science and Technology (KNUST) and Terre des hommes Foundation (Tdh)

Commitment of USD 22.2 Million Increases Takeda’s Total Global CSR Program Contributions to USD 260.9 Million Across 42 Diverse Collaborations Worldwide, With 20 Currently Ongoing in 42 Countries

 

(BUSINESS WIRE) -- Takeda (TSE:4502/NYSE: TAK) announced that it has awarded a total of USD 22.2 million to four new Global Corporate Social Responsibility (CSR) partners as part of the company’s ongoing commitment to supporting climate-resilient health systems in low- and middle-income countries around the world and aligned with the company’s purpose of better health for people, brighter future for the world. As climate change, extreme weather events and shifting global aid priorities continue to challenge healthcare access, Takeda is advancing its 2026 collaborations with the goal of expanding equitable access, strengthening health system resilience and improving patient outcomes. These efforts focus on locally led solutions that enhance health infrastructure, prepare the healthcare workforce and leverage innovation to sustain essential services for climate-vulnerable communities.

“Takeda has made a generational promise to improve health, and for the last 10 years, our Global CSR Program has given our people a meaningful way to put that promise into practice,” said Giles Platford, president of the International Business Unit at Takeda. “Significant, sustainable impact takes more than a single investment. It requires working with local partners who understand the needs in their communities and can help strengthen the systems people rely on. We are proud to support this year’s awardees as they address the challenging effects of climate change on healthcare systems and patients.”

Takeda’s commitments to these new awardees in 2026 include:

USD 6.4 million to Corus International. Linking climate-adaptive early warning, resilient service delivery and disaster preparedness aiming to protect the continuity of essential health services in Nepal.

“Climate shocks are reshaping where and when diseases strike, and too often the communities with the least warning are most impacted,” said Daniel V. Speckhard, President & CEO of Corus International. “Thanks to Takeda's generous support and partnership, Corus will help communities in Nepal predict outbreaks before they spread, strengthen health facilities against climate disasters, and equip communities to respond early. Together, we're building an early warning model that will be sustained by government and can be scaled beyond Nepal.”

USD 6.1 million to Humanity & Inclusion Handicap International. Strengthening inclusive, climate-resilient health systems by increasing workforce capacity, community preparedness and accessible facility adaptation in Honduras and Peru.

“We are honored to be selected as a Takeda Global CSR Program FY2026 awardee,” said Manuel Patrouillard, General Director of Humanity and Inclusion Handicap International. “This project makes a stronger alliance to support communities facing climate-related health risks, especially children, older adults, and people with disabilities across Honduras and Peru.”

USD 5.1 million to Kwame Nkrumah University of Science and Technology (KNUST). Readying the pharmacy workforce as frontline workers, advancing climate-responsive care through capacity building and greener practices in Ghana.

“Takeda's support gives us an excellent opportunity to put pharmacists right at the heart of how we respond to climate change and health,” said Prof. Christian Agyare, Vice Chancellor of KNUST. “Through PharmAdapt project we will train our pharmacists, prepare them for emergencies, and build standards that will last well beyond this project. This partnership means KNUST, supported by Takeda, can lead the way in creating practical tools and lessons that other countries across West Africa, and beyond, can learn from.”

USD 4.6 million to Terre des hommes Foundation (TdH). Supporting the building of climate resilient primary healthcare through facility retrofits, early warning and community preparedness in Egypt and Lebanon.

“I am deeply grateful for Takeda’s support. This partnership represents an important investment in the health and resilience of vulnerable communities in Egypt and Lebanon, helping pregnant women, newborns, and children access climate-resilient and environmentally sustainable health services,” said Barbara Hintermann, Director General of Tdh. “This collaboration will generate critical evidence on what works, helping to shape scalable solutions and inform policies that strengthen health systems and safeguard children’s future in an increasingly climate-affected world.”

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects”, “forecasts”, “outlook” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including drug pricing, tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at https://www.sec.gov/. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260917571464/en/

Permalink

https://www.aetoswire.com/en/news/1809202657412

Contacts

Tsuyoshi Tada (Tokyo)

toiawase_kouhou@takeda.co.jp

Kristi Bond (Boston)

Media_Relations@takeda.com

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces

 WASHINGTON - Saturday, 19. September 2026 AETOSWire  

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand.

 

(BUSINESS WIRE)--International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim.

Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide.

Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than USD 600 million) tied to a single currency exchange transaction of $150,000, a matter his legal team maintains has been mischaracterized in Thai media reporting.

"I have reviewed the facts of this case closely, and what I see is an unexplained level of enforcement that is wildly disproportionate to the underlying transaction," said Genser. "When a routine currency exchange leads to a freeze of this scale, when primary KYC responsibility properly sits with the regulated exchange rather than the end recipient, and when a six-year-old's savings account is drawn into proceedings with threats of detention, these are the kinds of due process questions the international community should be asking. I'm joining this effort because those questions deserve answers."

Genser's involvement adds an internationally recognized voice to a case that has drawn growing attention from investors, legal observers, and human rights advocates watching Thailand's use of its anti-money laundering and forfeiture powers.

Robert Seiden, founder of Seiden Law LLP and Yim Leak's chief global counsel, has represented a broad range of high-profile domestic and international clients across corporate, litigation, and reputational matters, including prior work for the Trump Organization.

Lanny J. Davis, an internationally renowned media spokesperson and defender of high-profile and private individuals targeted by reputational smears, who advised both Presidents Bill Clinton and George W. Bush, has joined Mr. Genser.

"We are looking closely at the Thai government's complicity, and indeed willful blindness, in allowing a Thailand-based clique to engage in a sustained campaign of lies and smears against Mr. Yim," said Davis, a globally recognized human rights advocate and former White House Special Counsel to the President. "Conduct like this raises serious human rights concerns." He added, "We will investigate, expose, and prosecute anyone who continues to abuse the media and governments for their own benefit."

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260918034322/en/

Permalink

https://www.aetoswire.com/en/news/1909202657423

Contacts

For media inquiries:

Contact Lanny Davis Public Relations at ldavis@lannyjdavis.com or +1 (202) 744-2792

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital

 Doha, Qatar - Friday, 18. September 2026 AETOSWire Print 

 

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm.

As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs.

The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance operational efficiency, service quality and customer experience. All proposals will remain subject to feasibility studies, Shahba Bank Board decisions, relevant General Assembly approvals, and applicable regulatory and supervisory approvals.

Mr. Moutaz Al-Khayyat, Chairman of Estithmar Holding, said:

“This investment reflects our confidence in Syria’s economic potential and Estithmar Holding’s approach to pursuing strategic opportunities that contribute to sustainable growth. We have a long-term vision for Shahba Bank and aspire to strengthen its capabilities and support its continued development, enabling the Bank to deliver modern and effective banking services that meet the evolving needs of individuals and businesses, while supporting the Syrian economy.”

Mr. Mohammad Safwat Raslan, Governor of the Central Bank of Syria, said:

“The entry of new institutional investment into the Syrian banking sector represents a positive step towards strengthening the sector’s capabilities and its role in serving the national economy. We welcome credible investments that uphold strong standards of governance, compliance and risk management.

Mr. Basel Shaddad, CEO of Estithmar Holding, said:

“The Shahba Bank stake transfer is a decisive step that strengthens Estithmar Holding’s leadership in the region’s financial sector. With our market capitalization now above USD 5 billion, we are advancing our long-term investment strategy with strong confidence in Syria’s economic resurgence and in building institutions that support sustainable growth.”

Fadi Salim Al Faqih, Group CEO of Estithmar Capital, said:

“This investment marks the beginning of a new phase in our shareholding in Shahba Bank. Through Masaref Holding, we will work with the Bank’s Board of Directors and relevant governing bodies to assess initiatives and modern banking products and services that strengthen the Bank’s capabilities and serve the Syrian economy, in accordance with established governance frameworks.”

Permalink

https://www.aetoswire.com/en/news/esth1892026e

Contacts

Estithmar Holding

Aida Bouassida

media@estithmarholding.com

Former Colombian President Iván Duque Appointed to Advance ICC and Carbon Measures' Global Product-Level Carbon Accounting Initiative

 Duque will chair the ICC & Carbon Measures Technical Expert Panel Advisory Group, bringing policy, business and practitioner perspectives into the next phase of their work.

 

(BUSINESS WIRE)--The International Chamber of Commerce (ICC) and Carbon Measures today announced that Iván Duque Márquez, former President of Colombia, has been named Chair of the newly created Technical Expert Panel Advisory Group established to complement the work of the TEP on Carbon Accounting.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915635710/en/

The TEP, co-convened by ICC and Carbon Measures, brings together recognized experts from academia, financial accounting, industry and civil society to develop a globally applicable carbon emissions accounting framework. The TEP’s work comes amid growing global momentum toward harmonization of carbon accounting.

The Advisory Group was created to take the TEP’s technical work to the next level, broadening engagement with policymakers, business leaders, and other stakeholders.

While the TEP’s technical conclusions are completely independent, the Advisory Group chaired by former President of Colombia Iván Duque will advise and provide different external perspectives to that work, bringing together leaders from across sectors and geographies to provide strategic input, help ensure business relevance and real-world applicability.

Additional members of the Advisory Group will be announced in the coming months, bringing together diverse perspectives from across sectors and geographies as the TEP continues to advance its technical work.

"President Duque’s appointment marks an important step for this initiative. His leadership and experience will help us build engagement across key stakeholder groups – advancing the wider conversation on the potential utility of a globally consistent product-level carbon accounting regime," said Andrew Wilson, ICC Deputy Secretary General.

The Panel’s Guiding Principles and comprehensive Landscape Review establish a common foundation by assessing existing approaches and identifying where gaps remain. The next phase for the TEP’s work is to develop a globally applicable carbon accounting framework, building on the progress already made and drawing on the practical experience of professionals doing this work every day.

As Chair, Duque will help deepen engagement with business leaders, policymakers and practitioners. Drawing on his experience in government and economic development, he will foster opportunities for technical dialogue, active listening and co-creation around what implementation will require in practice.

“It is a great honor to join the Carbon Measures team and contribute to accelerating the advancement of the highest standards in climate accounting,” said Iván Duque, Chair of the TEP Advisory Group. “This will contribute to developing more and better projects, while enhancing transparency in the mobilization of capital toward decarbonization.”

Duque brings extensive experience across government, economic development and climate policy to the role. As President of Colombia from 2018 to 2022, his administration committed the country to reducing greenhouse gas emissions by 51% by 2030 and achieving carbon neutrality by 2050. Those commitments were subsequently enshrined in Colombia’s 2021 Climate Action Law. Previously, Duque spent more than a decade at the Inter-American Development Bank, and since leaving office has remained active on global climate, conservation and economic development issues through work with organizations including Conservation International, the Bezos Earth Fund and Concordia, where he launched the Concordia Amazon Initiative.

“Getting the technical work right is essential, but it’s only part of the equation. If we want to build a carbon accounting framework that works across real-world supply chains, we need input from businesses, policymakers and other leaders who understand how it needs to work on the ground,” said Amy Brachio, CEO of Carbon Measures. “President Duque understands firsthand how economic growth, public policy and climate action intersect. I’m thrilled to have him leading the Advisory Group and helping us bring more voices into the process as the TEP moves its work forward.”

About International Chamber of Commerce

The International Chamber of Commerce (ICC) is the institutional representative of more than 45 million companies in over 170 countries. ICC’s core mission is to make business work for everyone, every day, everywhere. Through a unique mix of advocacy, solutions and standard setting, we promote international trade, responsible business conduct and a global approach to regulation, in addition to providing market-leading dispute resolution services. Our members include many of the world’s leading companies, SMEs, business associations and local chambers of commerce.

About Carbon Measures

Carbon Measures is a global coalition of leading businesses committed to advancing a ledger-based carbon accounting framework that provides accurate, verifiable, and timely company- and product-level data. Additionally, Carbon Measures is calling for product-level carbon intensity policies that unlock innovation, competition and market-based solutions to reduce emissions. To learn more about Carbon Measures, please visit carbonmeasures.org.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260915635710/en/

Permalink

https://www.aetoswire.com/en/news/1709202657383

Contacts

MEDIA CONTACTS

randa.eltahawy@iccwbo.org

media@carbonmeasures.org

Medisca Launches Global Peptide Division

 New division brings API-grade peptides and Medisca’s quality-first pharmaceutical expertise to a rapidly evolving area of personalized medicine

 

(BUSINESS WIRE)--Medisca today announced the launch of Medisca Peptides, a dedicated global division focused on expanding access to API-grade peptides and building an integrated peptide platform for pharmaceutical and personalized medicine markets worldwide. As the peptide landscape evolves, Medisca is proactively building the capabilities and infrastructure needed to support API-grade peptides within applicable regulatory frameworks.

The launch represents a significant long-term commitment to peptides, including the expansion of Medisca’s portfolio, strategic manufacturing relationships, and the pharmaceutical infrastructure needed to support the category’s growth. It also signals Medisca’s ambition to become a leading force in the next generation of peptide innovation.

For Medisca, the opportunity is familiar.

More than 35 years ago, the company was founded to help close the gap between the pharmaceutical standards compounders needed and the quality ingredients they could readily access. Today, as peptides emerge as an important area of pharmaceutical innovation and personalized medicine, Medisca sees another defining moment for the industry; one where quality, regulatory responsibility and responsible access will be critical to the category’s future.

The category is growing. Medisca intends to help define the standard.

“When I founded Medisca, I saw an opportunity to bring pharmaceutical compounding closer to the standards of traditional pharma by giving compounders better access to API-grade ingredients and holding those ingredients to a higher standard,” said Antonio Dos Santos, Founder and Chief Executive Officer of Medisca. “Today, I see a similar opportunity with peptides. We are not entering this space to follow it. We intend to help shape it.”

Defining a higher standard for peptide quality

Medisca’s approach begins at the source. The company has selected established manufacturing partners that share its quality-first mindset, prioritizing pharmaceutical experience, demonstrated quality systems, manufacturing expertise, and strong quality and compliance practices.

Medisca will apply established processes for manufacturer qualification, product testing, documentation and supply-chain oversight to the peptide APIs it brings to market. These controls are particularly important for peptides, where manufacturing complexity, characterization, purity, and peptide-related impurities present distinct quality considerations. Medisca is committed to operating within applicable regulatory frameworks and supporting responsible access to peptide APIs.

Building an Integrated Peptide Platform

Medisca Peptides extends beyond API supply, bringing together formulation expertise, compounding technologies and equipment, analytical services, education and technical support.

By connecting these capabilities within one platform, Medisca aims to support healthcare professionals and pharmaceutical partners with both the ingredients and expertise needed to navigate the evolving peptide landscape.

“Healthcare professionals and pharmaceutical partners need confidence in the quality and source of a peptide API, but they also need the expertise and infrastructure to put innovation into practice,” said Charlie Guerini, Chief Commercial Officer of Medisca. “That is what we are building with Medisca Peptides: an integrated platform that brings together a growing API portfolio, carefully selected manufacturing partners, reliable supply and the technical expertise our customers have trusted for decades.”

Shaping the Future of Peptide Innovation

The launch marks the beginning of a broader, multi-year strategy to establish Medisca as a global leader in peptide quality, supply and innovation.

Medisca will expand its peptide API portfolio and strategic manufacturing relationships while investing in the scientific, analytical, formulation, technical and educational capabilities needed to advance opportunities across pharmaceutical and personalized medicine.

Beyond supply, Medisca will take an active leadership role in shaping the future of peptides, advocating for added guardrails, transparency, responsible access and appropriate quality standards while working alongside manufacturers, healthcare professionals and industry stakeholders as science, regulation and clinical practice evolve.

The ambition is clear: to help define the next generation of peptides by bringing together the quality, expertise and integrated solutions needed to advance the category.

Medisca Peptides will begin rolling out across select global markets, with additional portfolio, strategic partnership and capability announcements to follow.

About Medisca

Founded in 1989, Medisca is a leader in personalized medicine and pharmaceutical supply chain solutions, with a vast portfolio of over 2,000 products completed by a library of 10,000+ proprietary and customized medication formulas, expertise and services in pharmaceutical compounding, continuing healthcare education, and analytical testing. Providing finely-tuned solutions to diverse wellness sectors in numerous markets globally, Medisca is bridging the gaps in healthcare and empowering personalized wellness for all. For more information, visit www.medisca.com and follow us on LinkedIn, Facebook, and YouTube.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260917717977/en/

Permalink

https://www.aetoswire.com/en/news/1709202657395

Contacts

Medisca Communications

communications@medisca.com

1-800-665-6334

Brushing Well Is Harder Than Most People Think — New Research Confirms Why the Technology Behind Oral-B iO is the Best Way to Help You Get it Right

 GENEVA - Thursday, 17. September 2026

Ranked #1 for plaque removal and gingivitis reduction, Oral-B iO's oscillating-rotating technology, paired with its unique round brush head, delivers a superior clean that helps people brush better every day, remove more plaque, and improve their gum health for healthier teeth for life.

 

(BUSINESS WIRE)--Oral-B, the #1 toothbrush brand used and recommended by dentists worldwide, today announced new evidence reinforcing the superiority of Oral-B iO technology. In an independent 2026 peer-reviewed network meta-analysis of 19 randomized clinical studies involving more than 1,300 participants, the oscillating-rotating technology behind Oral-B iO was ranked #1 for plaque removal and gingivitis reduction.

Most people think they are brushing effectively, but brushing well is harder than it seems. Plaque often remains in the places that are hardest to clean, including along the gumline, between teeth and around molars. In fact, 80% of people miss at least one area when brushing, and 60% miss their molars. Over time, that plaque buildup can impact oral health and well-being.

“People brush every day, but brushing effectively in the areas that matter most is not always easy,” said Svetlana Farrell, DDS, PhD, Sr. Director, Oral Health Sciences & Professional Scientific Relations. "Oral-B iO was designed around a simple reality: brushing well is harder than most people think. It helps make a superior clean easier to achieve by guiding people to brush more thoroughly and with the right pressure."

The proof is clear: Oral-B iO cleans better

Across 19 randomized clinical studies involving more than 1,300 participants, the oscillating-rotating technology behind Oral-B iO was ranked first for plaque removal and gingivitis reduction in an independent 2026 peer-reviewed network meta-analysis.

The findings add to a broader body of evidence supporting Oral-B superiority, including more than 120 peer-reviewed publications on Oral-B round-head technology and cleaning performance.

Study after study confirms Oral-B iO technology cleans better, removing more plaque and helping people achieve healthier gums. Oral-B iO removes 100% more plaque than a manual toothbrush and delivers 100% healthier gums. Clinical evidence shows Oral-B iO helps 88% of people with early gum problems get back to healthy gums, four times more than manual brushing, and is 60% more effective than a premium sonic toothbrush along the gumline, where gum issues often persist.

“Effective plaque control is foundational to gum health, but many patients struggle to maintain the right technique, brushing time, pressure and coverage at home,” said Prof. Liran Levin, Professor of Periodontology and the Chair of the Department of Specialty Dentistry at the Northeast Ohio Medical University. “What stands out in this evidence is that Oral-B iO is not only shown to remove more plaque and support healthier gums, but also it is designed to help people brush thoroughly, use the right pressure and sustain better brushing every day. That is where innovation can make a meaningful difference between dental visits.”

Brushing well is harder than most people think and not all brushes, even power brushes, clean the same. Oral-B iO makes a superior clean easier.

Oral-B iO's superiority starts with its oscillating-rotating technology, paired with Oral-B's unique dentist-inspired round brush head, to make a superior clean easier to achieve. The round head surrounds and adapts to each tooth, helping remove plaque where it builds most. Synchronized rotations, micro-vibrations and smart pressure guidance help people brush more completely, clean thoroughly yet gently, avoid brushing too hard, and reach difficult-to-clean areas with less effort.

Simply by switching to iO, people already brush better: research shows 84% of people reached all inside surfaces of teeth after one week of use, significantly more than earlier research showing only 44% with manual brushing.

Better brushing habits start early

The challenge is even more important for children who are still learning how to brush effectively. Good oral-health habits start early, but children need help building the motivation, technique and twice-daily routine that make effective brushing easier to sustain over time.

Oral-B iO Kids helps make brushing easier and more engaging. In product-use research, 90% of children say they love brushing with Oral-B iO Kids, 84% of parents say their child is motivated to brush twice a day for two minutes, 83% of children say the toothbrush makes them want to brush more often, and 88% of children say Oral-B iO Kids makes it easy to brush all areas of their mouth.

Oral-B iO Kids removes 1.5x more plaque than a manual toothbrush, including in hard-to-clean molars, and is the only electric toothbrush technology to have earned the European Academy of Paediatric Dentistry, EAPD, Seal of Approval for children aged 3+.

“Between work, school, and activities, life gets hectic, and our daily routines don’t always match our best intentions,” said Dr. Jeanette MacLean, DDS, Diplomate, American Board of Pediatric Dentistry, Fellow, American Academy of Pediatric Dentistry. “As a pediatric dentist and a mom, I appreciate features that get kids more interested in brushing, help them take their time, and reach the spots they tend to miss. It’s a little extra help to support healthy habits we ask them to do every day.”

A superior clean is a smart investment in healthier mouths for life

Better brushing habits and healthier gums do more than improve everyday oral health. They can also help reduce the need for more intensive treatment over time. Oral health is connected to overall wellbeing, and prevention at home can help reduce future treatment needs, discomfort and cost over time. A P&G and American Academy of Family Physicians survey found that many people care about oral health, but very few spontaneously connect oral health with whole-body health, highlighting an opportunity to make daily oral care feel more like an act of prevention.

Prevention also matters for the environment. A peer-reviewed life cycle assessment published in the Journal of Dentistry found that managing advanced periodontal disease can be associated with up to approximately 10 times higher environmental impact compared with maintaining periodontal health through at-home prevention. The study also found that clinical interventions account for about 90% of total environmental impact across the modeled periodontal pathway, reinforcing prevention at home as an important lever for patients, healthcare systems and the environment.

“A superior clean is not just about how your teeth feel today,” said Svetlana Farrell, DDS, PhD, Sr. Director, Oral Health Sciences & Professional Scientific Relations. “By helping people remove more plaque, maintain healthier gums and support healthier mouths, Oral-B iO helps turn daily brushing into a simple habit that supports long-term oral health.”

Designed for real mouths and real brushing habits

Oral-B iO was designed around a simple truth: every mouth is different. Real mouths have curves, tight spaces, hard-to-clean molars and areas people often miss. Oral-B’s unique round head surrounds and adapts to each tooth, while advanced technology helps guide people to clean thoroughly yet gently, use the right pressure, and build better brushing habits.

For consumers, Oral-B iO makes a superior clean easier to achieve every day. For parents, Oral-B iO Kids helps make better brushing more engaging and easier to support. For dental professionals, Oral-B iO helps patients turn advice into action between visits.

Because when brushing well is harder than most people think, the best technology is the one that makes getting it right easier, every day. No wonder why Oral-B is the #1 toothbrush brand used and recommended by dentists worldwide and trusted by millions of consumers around the world.

About Oral-B

Oral-B® was founded in 1950 by a California periodontist, who invented an innovative toothbrush to help his patients achieve healthier teeth and gums at home. Oral-B® continues to stay true to his mission and is today the worldwide leader in the over $5 billion brushing market. Part of the Procter & Gamble Company, the brand manufactures electric toothbrushes and toothpaste for adults and children, oral irrigators, and interdental products.

About Procter & Gamble

P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide. Please visit https://www.pg.com for the latest news and information about P&G and its brands. For other P&G news, visit us at https://www.pg.com/news.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260911054017/en/

Permalink

https://www.aetoswire.com/en/news/1709202657390

Contacts

For more information please contact:

Cristina Morillogomez, morillogomez.c@pg.com